)
Visual12 Dec 2025
On: expanding revenue and profitability
Apellis Pharmaceuticals (APLS) investor relations material
Apellis Pharmaceuticals Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary3 Dec, 2025
Empaveli launch progress and market dynamics
Launch in C3G and IC-MPGN is proceeding as planned, with patient identification and onboarding exceeding expectations.
Estimated 5,000 patient population aligns with internal projections, despite competitors' higher estimates.
Pediatric and post-transplant segments show higher urgency and engagement, with unique label advantages.
Physician adoption is steady, with momentum building as more nephrologists gain experience and share positive outcomes.
Expectation for increased adoption in transplantation settings by 2026 as protocols evolve.
SYFOVRE and geographic atrophy market trends
Geographic atrophy market faced headwinds in 2025 due to loss of foundation copay assistance, impacting new patient starts.
Practices are adapting, with renewed interest in advanced GA patients and plans to expand into early GA and wet AMD segments.
Long-term GALE data shows five years of treatment can save 1.5 years of vision, supporting future positioning.
Main mission for 2026 is to help physicians reimagine GA management and highlight functional benefits.
Normalcy is returning to retina practices, creating more opportunity for GA treatment uptake.
Innovation and competitive positioning
Prefilled syringe for SYFOVRE expected to launch toward end of next year, anticipated to improve workflow and adoption.
No competitor currently offers a prefilled syringe, providing a potential differentiator.
Market share has remained stable, with mid-50% for SYFOVRE and 45% for competitor; no major shifts expected absent new innovations.
RNAi program (Abelast 3007) aims for less frequent dosing and greater efficacy, with commercial strategy aligned for future rollout.
Impact of unique label in pediatric/transplant
Retina market recovery from co-pay issues
Prefilled syringe impact on SYFOVRE adoption
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Apellis Pharmaceuticals earnings date
Q4 202527 Feb, 2026
Next Apellis Pharmaceuticals earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Apellis Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for autoimmune and rare diseases. The company’s research is centered around complement inhibition, targeting the C3 protein in the complement system, which plays a key role in immune response. Apellis’ lead products and drug candidates aim to treat conditions such as geographic atrophy (a form of age-related macular degeneration) and paroxysmal nocturnal hemoglobinuria (PNH), among other serious diseases. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage